EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors

Yasutaka Yamada, Kodai Sato, Shinichi Sakamoto, Takuya Tsujino, Sinpei Saito, Kazuki Nishimura, Tatsuo Fukushima, Ko Nakamura, Yuki Yoshikawa, Tomohisa Matsunaga, Ryoichi Maenosono, Manato Kanesaka und 14 weitere

International Journal of Clinical Oncology · 2025-03 · 30 (3) · 539-550

DOI: 10.1007/s10147-024-02676-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 10.12.2024. Verfasst von Yasutaka Yamada und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-City, Chiba, 2608670, Japan. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Tosyl Compounds, Prostatic Neoplasms, Nitriles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science London, Uehara Memorial Foundation, Astellas Foundation for Research on Metabolic Disorders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study investigated the characteristics of prostate-specific antigen (PSA) dynamics when androgen receptor signaling inhibitor (ARSI), or vintage agent (bicalutamide) was used for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Patients and methods A total of 213 mHSPC patients from each of the ARSI and bicalutamide groups treated between 2015 and 2022 were selected from multiple institutions using propensity score-matched analysis to align backgrounds. PSA progression-free survival (PFS) and overall survival (OS) were assessed. PSA level at 3 months, PSA nadir level, and time to PSA nadir were examined to analyze of PSA kinetics.

Results

ARSI treatment significantly improved PSA PFS compared to bicalutamide ( P = 0.0063), although no significant difference in OS was seen ( P = 0.3134). No significant differences were observed between treatment groups in median PSA levels at 3 months (1.47 vs 0.52 ng/ml, P = 0.3042) or PSA nadir levels (0.263 vs 0.1345 ng/ml, P = 0.1228). Bicalutamide treatment demonstrated longer time to nadir than ARSI in progression-free cases (median: 243 vs 213.5 days, P = 0.0003). Survival tree analysis found that PSA nadir ≤ 1.5 ng/ml and time to nadir ≥ 145 days were the optimal cut-offs for best stratifying OS with bicalutamide, while PSA nadir ≤ 0.45 ng/ml and time to nadir ≥ 70 days were optimal with ARSI.

Conclusion

No significant differences in PSA response was seen between groups; however, distinct optimal cut-offs were demonstrated for PSA nadir and time to nadir. The present findings will be useful for optimal PSA monitoring for mHSPC patients and for early identification of poor-prognosis populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenTosyl CompoundsProstatic NeoplasmsNitrilesAnilidesAndrogen Receptor AntagonistsHumansMaleAgedMiddle AgedReceptors, AndrogenProgression-Free SurvivalAged, 80 and overNeoplasm MetastasisRetrospective StudiesTreatment OutcomeSignal TransductionAndrogen Antagonists

Stichwörter der Autor:innen

Androgen receptor signaling inhibitorBicalutamideMetastatic hormone-sensitive prostate cancerPSA dynamicsPSA nadirTime to PSA nadir

Substanzen

Prostate-Specific AntigenTosyl CompoundsNitrilesAnilidesbicalutamideAndrogen Receptor AntagonistsReceptors, AndrogenAR protein, humanAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-City, Chiba, 2608670, Japan.
  • Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-City, Chiba, 2608670, Japan. rbatbat1@gmail.com.
  • Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Department of Urology, Chibaken Saiseikai Narashino Hospital, Chiba, Japan.
  • Department of Urology, Kimitsu Chuo Hospital, Chiba, Japan.
  • Department of Urology, Funabashi Municipal Medical Center, Chiba, Japan.

Förderung

  • Japan Society for the Promotion of Science London
  • Uehara Memorial Foundation
  • Astellas Foundation for Research on Metabolic Disorders
  • Nippon Shinyaku

Zitieren

APA

Yamada, Y., Sato, K., Sakamoto, S., Tsujino, T., Saito, S., Nishimura, K., Fukushima, T., Nakamura, K., Yoshikawa, Y., Matsunaga, T., Maenosono, R., Kanesaka, M., Arai, T., Sazuka, T., Imamura, Y., Komura, K., Mikami, K., Nakamura, K., Fukasawa, S., …, & Ichikawa, T. (2025). Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors. International Journal of Clinical Oncology, 30(3), 539-550. https://doi.org/10.1007/s10147-024-02676-z

Vancouver

Yamada Y, Sato K, Sakamoto S, Tsujino T, Saito S, Nishimura K, et al. Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors. International Journal of Clinical Oncology. 2025;30(3):539-550. doi:10.1007/s10147-024-02676-z

BibTeX
@article{Yamada2025,
  author = {Yamada, Yasutaka and Sato, Kodai and Sakamoto, Shinichi and Tsujino, Takuya and Saito, Sinpei and Nishimura, Kazuki and Fukushima, Tatsuo and Nakamura, Ko and Yoshikawa, Yuki and Matsunaga, Tomohisa and Maenosono, Ryoichi and Kanesaka, Manato and Arai, Takayuki and Sazuka, Tomokazu and Imamura, Yusuke and Komura, Kazumasa and Mikami, Kazuo and Nakamura, Kazuyoshi and Fukasawa, Satoshi and Chiba, Kazuto and Naya, Yukio and Nagata, Maki and Komaru, Atsushi and Nakatsu, Hiroomi and Azuma, Haruhito and Ichikawa, Tomohiko},
  title = {Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  volume = {30},
  number = {3},
  pages = {539--550},
  doi = {10.1007/s10147-024-02676-z}
}
Kostenlos starten →